We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Antibiotic Susceptibility Testing Evaluated in General Practice

By LabMedica International staff writers
Posted on 16 Nov 2017
Urinary tract infection (UTI) is a common condition in general practice and the second leading cause for the prescribing of antibiotics. More...
Urine culture gives a definite answer for UTI in the symptomatic patient.

However, sending urine to the microbiological laboratory for culture and susceptibility testing can delay treatment for several days. Point-of- care (POC) tests for urine culture and urine culture susceptibility testing are commercially available. They can provide a result within 24 hours, a delay to treatment, which the majority of patients would accept.

Scientists at the University of Copenhagen (Denmark) carried out an individually randomized controlled trial to investigate the effect of adding POC susceptibility testing to POC culture on appropriate use of antibiotics as well as clinical and microbiological cure for patients with suspected uncomplicated urinary tract infection (UTI) in general practice. The participants in the trial were women with suspected uncomplicated UTI, including elderly patients above 65, patients with recurrent UTI and patients with diabetes.

The participants were divided into groups and the culture-only group was tested with The ID Flexicult that is a chromogenic agar allowing identification and quantification of (1) E. coli, (2) other Enterobacteriaceae (Gram-negative rods), (3) enterococci, (4) Proteus spp., (5) Staphylococcus saphrophyticus and (6) Pseudomonas aeruginosa. The Flexicult SSI-Urinary Kit was used for the culture and susceptibility testing group. This kit consists of an agar dish consisting of a large compartment containing the same agar material as in the ID Flexicult and five small compartments, each containing agar with a specific antibiotic. Urine samples were also sent to a reference laboratory and were analyzed on Inoqul A Bi-plate with CHROMagar and blood agar with 10 μL on each half of the agar.

The team had from 20 general practices recruited 191 patients for culture and susceptibility testing and 172 for culture only. They report that 63% of the patients had UTI and 12% of these were resistant to the most commonly used antibiotic, pivmecillinam. Patients randomized to culture only received significantly more appropriate treatment (OR: 1.44). There was no significant difference in clinical or microbiological cure.

The team concluded that adding POC susceptibility testing to POC culture did not improve antibiotic prescribing for patients with suspected uncomplicated UTI in general practice. Susceptibility testing should be reserved for patients at high risk of resistance and complications. If all patients had been treated with first-line antibiotics based on clinical history and positive dipstick finding, then about 45% of patients would have been inappropriately treated compared with 29% in the study. The study was published on October 18, 2017, in the journal BMJ Open.

Related Links:
University of Copenhagen


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.